logo-loader
viewAdmedus Ltd

Admedus sells 12,500 units of CardioCel® and VascuCel® patches to Le Maitre Vascular Inc

LeMaitre Vascular is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition affecting more than 200 million people worldwide.

Admedus Ltd - Admedus sells 12,500 units of CardioCel® and VascuCel® patches to Le Maitre Vascular Inc
Admedus is a structural heart company focusing on next generation technologies

Admedus Limited (ASX:AHZ) confirms that LeMaitre Vascular Inc (NASDAQ:LMAT) has placed an order for about 12,500 units of CardioCel® and VascuCel® patches for the year ahead.

The quantity exceeds the company’s unit sales for the products over the previous 12 months.

Admedus sold distribution rights to its CardioCel® and VascuCel® patch business to LeMaitre on October 14 for A$22.8 million upfront, reflecting the A$21.2 million received on the completion date plus the proceeds to be paid by LeMaitre on delivery of stock ordered on completion of the transaction.

This will be followed by two deferred payments of $1 million each over the next 12 to 36 months while additionally, the company may receive up to $11.4 million in milestone payments.

Shares were up almost 8% to an intra-day high of 9.7 cents after reaching a new 12-month of 10.5 cents on November 19.

Under the sale agreement, Admedus retained exclusive manufacturing rights for up to three years to supply LeMaitre with products.

The manufacturing agreement ensures Admedus a 20% margin over cost.

Terms and conditions

The agreement terms provide earnout payments:

  • Up to A$3.73 million if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $29.8 million in the first 12 months or $1.8 million if gross revenue from product sales exceed $22.4 million in the first 12 months;
  • Up to $3.73 million if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $44.7 million in the second 12 months or $1.8 million if gross revenue from product sales exceed $33.5 million in the second 12 months;
  • $3 million on obtaining certain regulatory approvals under European Medical Devices Directorate Regulation;
  • $700,000 on Admedus completing all testing and documentation to extend the shelf life of the CardioCel® and VascuCel® products from 36 months to at least 60 months in the United States; and
  • $200,000 for completion of reporting procedures by October 31.

Quick facts: Admedus Ltd

Price: 0.069 AUD

ASX:AHZ
Market: ASX
Market Cap: $40.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Admedus Ltd named herein, including the promotion by the Company of Admedus Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Admedus Ltd proud to unveil its valves publicly for the first time in London

Admedus Ltd's (ASX:AHZ) CEO Wayne Paterson caught up with Proactive's Andrew Scott while in London. The firm recently made what's been described as a transformational move to sell off its CardioCel® and VascuCel® patch business. Paterson says the focus is now firmly on the Adapt...

on 20/11/19

2 min read